Latest news with #LarsRasmussen
Middle East Eye
a day ago
- Politics
- Middle East Eye
We all want to recognise Palestine, says Danish minister
Recognising the state of Palestine is a question of timing, Danish Foreign Minister Lars Rasmussen has said, according to Reuters. The news agency quoted Rasmussen as saying: "We all want to recognise Palestine, so it is a question of timing." Finland's Foreign Minister Elina Valtonen has made similar comments, stating that her country is waiting for the right moment to recognise the state of Palestine. Finnish President Alexander Stubb announced earlier this month that the country was willing to recognise Palestine. Countries including the UK, France, Canada and Malta have said they will recognise Palestine in the upcoming session of the United Nations General Assembly.
Yahoo
08-08-2025
- Business
- Yahoo
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast's interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference webcast of the conference call will be available during and after the event. Coloplast will be represented by: Lars Rasmussen - Interim CEOAnders Lonning-Skovgaard - Executive Vice President, CFOAleksandra Dimovska - Vice President, Investor RelationsKristine Husted Munk - Senior Manager, Investor RelationsSimone Dyrby Helvind - Senior Manager, Investor Relations WebcastFor participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below: Dial-in detailsTo actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details. For more information, please contact: Aleksandra Dimovska - Vice President, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 2458. E-mail: dkadim@ Kristine Husted Munk - Senior Manager, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 3266. E-mail: dkkhu@ Simone Dyrby Helvind - Senior Manager, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 2981. E-mail: dksdk@ Julie Sommer Müggler - Coordinator & PA, Investor RelationsTel.: +45 4911 1800 / direct: +45 4911 3161. E-mail: dkjusm@ Coloplast will be available on individual phone lines after the conference call for further questions. Attachment Invitation to Coloplast 9M 2024-25 conference call on 19 August 2025Sign in to access your portfolio
Yahoo
03-06-2025
- Business
- Yahoo
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025
The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary purpose of the event is to give institutional investors and financial analysts an introduction to the new 5-year strategy for the company, as well as to provide the opportunity to meet with the broader Management day will start with a plenary session, covering the introduction of the new Group strategy, a financial update, and the strategy for the Chronic Care businesses. In the afternoon, participants will be split into groups and rotate between four Q&A breakout sessions. Participation in the breakout sessions will be in-person only (with a replay of the presentations available after the event).The formal program will end at 17.00, followed by an opportunity to meet the Coloplast management team in an informal setting. Agenda in CEST10.00 - 10.30 Registration10.30 - 12.30 Plenary session: Group strategy and financials, strategy for Chronic Care and Voice and Respiratory Care12.30 - 13.00 Lunch break13.00 - 17.00 Q&A breakout sessions (incl. breaks)17.00 - 18.30 Social activity (on premise) Coloplast representatives Plenary session: Lars Rasmussen, Interim President and CEO Anders Lonning-Skovgaard, Executive Vice President, CFO Nicolai Buhl, Executive Vice President, Chronic Care Caroline Vagner Rosenstand, Executive Vice President, Voice & Respiratory Care Breakout sessions: Chronic Care deep dive: Mike DelVacchio, Senior Vice President, North America Thomas Bruhn, Senior Vice President, Emerging Markets Advanced Wound Care: Fertram Sigurjonsson, Founder and President, Kerecis Bernd Greiner, Senior Vice President, Adv. Wound Dressings Interventional Urology: Thomas NP Johns Jr, Executive Vice President, Interventional Urology Global Operations and People & Culture: Allan Rasmussen, Executive Vice President, Global Operations Dorthe Rønnau, Executive Vice President, People & Culture In-person participationIf you wish to join us in-person and attend the plenary session and the Q&A breakout sessions, please register by sending an email to CMD2025@ stating your full name, company, contact phone number and itinerary (if relevant).Kindly register before Friday, 15 August 2025. Virtual participationVirtual participation will be possible for the plenary session.A link for the webcast of the plenary sessions will be available on our website closer to the date. For more information,please contact: Aleksandra Dimovska, Vice PresidentDirect tel.: +45 4911 2458E-mail: dkadim@ Simone Dyrby Helvind, Sr. Manager Direct tel.: +45 4911 2981E-mail: dksdk@ Julie Sommer Müggler, Coordinator Direct tel.: +45 4911 3161Email: dkjusm@ Attachment Coloplast CMD 2025 invitation
Yahoo
08-05-2025
- Business
- Yahoo
Coloplast AS (CLPBF) Q2 2025 Earnings Call Highlights: Navigating Growth Challenges and ...
Organic Growth: 6% in Q2, revised annual expectation to 7% from 8%-9%. EBIT Margin Before Special Items: 27% in Q2, revised annual expectation to 27%-28%. Return on Invested Capital: 15%, on par with last year. Revenue Increase: DKK765 million or 6% for the first six months. Gross Margin: 68% for the first six months, on par with last year. Operating Expenses: DKK5.7 billion, a 6% increase from last year. Operating Profit Before Special Items: DKK3.8 billion, a 5% increase compared to last year. Net Profit Before Special Items: DKK2.7 billion, a 7% increase compared to last year. Adjusted Diluted Earnings Per Share: Increased by 7% to DKK11.8. Operating Cash Flow: Inflow of DKK2.7 billion for the first six months. Free Cash Flow: Inflow of DKK2.3 billion for the first six months. Interim Dividend: DKK5 per share, total payout of approximately DKK1.1 billion. Advanced Wound Care Organic Growth: 11% for the first six months. Interventional Urology Organic Growth: 0% for the first six months. Continence Care Organic Growth: 7% for the first six months. Voice and Respiratory Care Organic Growth: 9% for the first six months. Warning! GuruFocus has detected 4 Warning Signs with CLPBF. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Coloplast AS (CLPBF) reported a 6% organic growth and a 27% EBIT margin before special items in the second quarter. The company has initiated several product launches in Chronic Care, including the Luja catheter, which is driving growth in Continence Care. Coloplast AS (CLPBF) continues to make progress in sustainability, maintaining a solid employee engagement score of 8.2, above the industry benchmark. The company has seen strong performance from its acquisitions, Atos Medical and Kerecis, which are performing in line with expectations. Free cash flow for the first six months was an inflow of DKK2.3 billion, a significant improvement compared to the previous year. Organic growth in Q2 was below expectations, impacted by a product recall in Interventional Urology and weaker performance in Ostomy Care. The growth rate for Interventional Urology has been adjusted to around 0% for the year, down from mid-single-digit growth expectations. The company revised its organic growth guidance for the year to around 7%, down from the previous 8% to 9%. There was a slowdown in growth in China, particularly impacting the Ostomy Care business. The EBIT margin expectations have been adjusted to 27% to 28%, down from the previous expectation of around 28%. Q: What improvements are needed to drive value creation and top-line growth? A: Lars Rasmussen, Chairman of the Board of Directors, emphasized the need for more decisiveness in management to enhance top-line growth. The company has good cost control but needs to focus on executing strategies that boost revenue, particularly through investments in acquisitions like Kerecis and Atos, and new product development. Q: Why has the recovery in bladder health been slower than expected, and what are the future expectations? A: Anders Lonning-Skovgaard, CFO, explained that the slower recovery is due to significant customer loss following a product recall. The company does not expect recovery in this segment until next year, leading to a revised growth forecast of around 0% for the year. Q: Will the upcoming Capital Markets Day include new financial targets for the next five years? A: Lars Rasmussen confirmed that the Capital Markets Day will present a full strategic update, including new financial targets for the next five-year period. Q: How is the company addressing the strategic rationale of retaining the Interventional Urology business given recent performance issues? A: Lars Rasmussen stated that the strategy for Interventional Urology is under review, and more details will be shared in September. The focus is on addressing internal issues that have impacted performance. Q: What are the expectations for the Ostomy Care business, considering the slowdown in China and developed markets? A: Anders Lonning-Skovgaard noted that Ostomy Care growth was below expectations due to a high baseline in Europe and slower tender activity in emerging markets. However, the company expects improvement in the second half of the year, driven by new innovations and market share gains. Q: Are the organic growth targets too ambitious given recent performance challenges? A: Lars Rasmussen acknowledged the targets are tough but emphasized the importance of having superior product offerings to achieve above-market growth. The company believes it deserves more growth based on its product quality and service levels. Q: What corrective actions are being taken to improve profitability and growth? A: Anders Lonning-Skovgaard mentioned that several initiatives are underway to enhance profitability, including restructuring costs and asset write-downs. More details will be provided in the Q3 call. Q: How is the company addressing the challenges in the Chinese market for Ostomy and Wound Care? A: Anders Lonning-Skovgaard explained that growth in China has slowed to low single digits due to consumer sentiment. However, the company still sees good growth in the hospital segment and remains confident in its long-term outlook. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
06-05-2025
- Business
- Bloomberg
Coloplast Seeks to Restore Investor Trust With Firing of CEO
Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That's according to Lars Rasmussen, the Danish company's chairman, who is now stepping in to become interim CEO while a search for a replacement for Kristian Villumsen is underway. The shares fell as much as 7.4% in Copenhagen trading, the most in a year.
